Find the Perfect Plan for Your Investment Journey
C
Latest price
52 Week Range
CA$0.15 - CA$0.59
Next Earnings Date
Apr 25 2025
Next Earnings Date
Apr 25 2025
Latest price
Market Cap | CA$20.65M |
EV | CA$36.44M |
Shares Outstanding | 118.00M |
Beta | 2.77 |
Analyst Rating | NOT_AVAILABLE |
Analyst Target Price | - |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | -7.20% |
EPS | - |
Operating Cash Flow | -14.40% |
Free Cash Flow | - |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | - |
ROCE 2024 | - |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
C
C21 Investments Inc.
CXXI
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Newman, Sonny
Employees
114
Website
www.cxxi.caIPO Date
1996-08-08
Headquarters
#170 – 601 West Cordova, Mailbox 107, Vancouver, British Columbia, V6B 1G1, Canada
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved